Targeting IKKß for the treatment of rheumatoid arthritis.

Bamborough, Paul; Morse, Mary A; Ray, Keith P

Bamborough, Paul; Morse, Mary A; Ray, Keith P.

Affiliation

Bamborough P; GlaxoSmithKline R&D, Medicines Research Centre, Stevenage, Hertfordshire, UK. paul.a.bamborough@gsk.com

Drug News Perspect ; 23(8): 483-90, 2010 Oct.

Article in En | MEDLINE | ID: mdl-21031164

Subject(s)

Arthritis, Rheumatoid/drug therapy; Drug Delivery Systems; I-kappa B Kinase/antagonists & inhibitors; Animals; Anti-Inflammatory Agents/pharmacology; Arthritis, Rheumatoid/genetics; Arthritis, Rheumatoid/physiopathology; Drug Design; Humans; I-kappa B Kinase/metabolism; NF-kappa B/antagonists & inhibitors; NF-kappa B/metabolism; Protein Kinase Inhibitors/pharmacology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Drug Delivery Systems / I-kappa B Kinase Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Drug News Perspect Journal subject: FARMACOLOGIA Year: 2010 Type: Article Affiliation country: United kingdom

Fulltext

XML

PubMed Links

Search on Google